Literature DB >> 8061430

Dynamic gadolinium-enhanced echo-planar MR imaging of the liver: effect of pulse sequence and dose on enhancement.

P Reimer1, S Saini, K K Kwong, M S Cohen, R Weissleder, T J Brady.   

Abstract

To develop guidelines for clinical magnetic resonance imaging of the liver, the authors undertook an animal study to investigate the effect of dose and pulse sequence on liver signal intensity in gadopentetate dimeglumine-enhanced echo-planar imaging. Serial imaging of the liver was performed in anesthetized rats after intravenous administration of five different doses (0.01, 0.05, 0.1, 0.2, and 0.5 mmol/kg) of contrast agent, with six different pulse sequences. The results show that gadopentetate dimeglumine-enhanced echo-planar images obtained during the perfusion phase can yield either positive (due to increased T1 relaxation rates) or negative (due to susceptibility-induced increased T2 relaxation rates) liver enhancement depending on choice of pulse sequence and dose. At the current clinically recommended dose of 0.1 mmol/kg, maximal liver signal enhancement was seen with a T1-weighted inversion-recovery sequence, while maximal liver signal diminution was seen with a T2*-weighted gradient-echo sequence. The authors conclude that gadopentetate dimeglumine-enhanced echo-planar imaging can provide T1, T2, and T2* contrast that may be exploited for both lesion detection and lesion characterization.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8061430     DOI: 10.1002/jmri.1880040318

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  1 in total

1.  Diagnostic Value of Semiquantitative Analysis of Dynamic Susceptibility Contrast Magnetic Resonance Imaging with GD-EOB-DTPA in Focal Liver Lesions Characterization: A Feasibility Study.

Authors:  Davide Ippolito; Maddalena Colombo; Chiara Trattenero; Pietro Andrea Bonaffini; Cammillo Talei Franzesi; Davide Fior; Sandro Sironi
Journal:  Gastroenterol Res Pract       Date:  2015-05-06       Impact factor: 2.260

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.